Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Given Average Rating of “Moderate Buy” by Analysts

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) has earned a consensus recommendation of “Moderate Buy” from the six analysts that are presently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, four have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $9.80.

A number of analysts have recently issued reports on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Aclaris Therapeutics in a research report on Friday, March 27th. Wedbush reiterated an “outperform” rating and set a $8.00 price target on shares of Aclaris Therapeutics in a research report on Tuesday, March 31st. Wall Street Zen upgraded Aclaris Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday. HC Wainwright reiterated a “buy” rating and set a $16.00 price target on shares of Aclaris Therapeutics in a research report on Thursday, March 19th. Finally, Craig Hallum assumed coverage on Aclaris Therapeutics in a research report on Friday, January 30th. They set a “buy” rating and a $10.00 price target for the company.

Aclaris Therapeutics Stock Down 1.3%

NASDAQ:ACRS opened at $3.75 on Wednesday. The stock has a market cap of $452.23 million, a P/E ratio of -7.08 and a beta of 0.67. The business’s 50-day moving average price is $3.48 and its two-hundred day moving average price is $2.93. Aclaris Therapeutics has a twelve month low of $1.05 and a twelve month high of $4.89.

Aclaris Therapeutics (NASDAQ:ACRS) last issued its quarterly earnings results on Thursday, February 26th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.01). The business had revenue of $1.30 million for the quarter, compared to the consensus estimate of $2.07 million. Aclaris Therapeutics had a negative net margin of 829.58% and a negative return on equity of 52.04%. On average, equities research analysts expect that Aclaris Therapeutics will post -0.82 EPS for the current fiscal year.

Hedge Funds Weigh In On Aclaris Therapeutics

A number of large investors have recently modified their holdings of ACRS. Three Bridge Wealth Advisors LLC purchased a new position in shares of Aclaris Therapeutics during the 3rd quarter valued at about $1,358,000. Squarepoint Ops LLC raised its holdings in shares of Aclaris Therapeutics by 11.9% during the 2nd quarter. Squarepoint Ops LLC now owns 390,583 shares of the biotechnology company’s stock valued at $555,000 after buying an additional 41,666 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in shares of Aclaris Therapeutics during the 2nd quarter valued at about $70,000. Persistent Asset Partners Ltd purchased a new position in shares of Aclaris Therapeutics during the 4th quarter valued at about $67,000. Finally, BNP Paribas Financial Markets raised its holdings in shares of Aclaris Therapeutics by 59.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 26,667 shares of the biotechnology company’s stock valued at $51,000 after buying an additional 9,894 shares in the last quarter. 98.34% of the stock is owned by hedge funds and other institutional investors.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc (NASDAQ:ACRS) is a clinical‐stage biopharmaceutical company focused on discovering, developing and commercializing novel small‐molecule therapies for dermatologic diseases and related rare disorders. The company’s pipeline includes several product candidates designed to address chronic inflammatory skin conditions and non‐melanoma skin lesions. Lead programs include ATI‐50002, a topical agent in late‐stage development for molluscum contagiosum removal; ATI‐50003 for common wart resolution; ATI‐1501, an oral JAK1/2 inhibitor targeting pruritic disorders; and ATI‐450, an oral MK2 inhibitor for inflammatory indications.

Founded in 2016 and headquartered in Malvern, Pennsylvania, Aclaris leverages proprietary chemistry platforms and translational research capabilities to advance multiple clinical and preclinical candidates.